Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

Next Previous
X
Search
Trial Profile

AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Amrubicin; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical

    • Most Recent Events

    • 11 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 08 Jan 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 19 Jul 2013 Planned end date (Oct 2015) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top